CLC Number:
- R473.56
| [1] 董奥,张智月,王晓梅,等.癌症患者经济毒性的研究进展[J]. 上海护理, 2022,22(7):53-58.DOI:10.3969/j.issn.1009-8399.2022.07.013. [2] Zafar SY, Abernethy AP.Financial toxicity, Part I: a new name for a growing problem[J]. Oncology (Williston Park), 2013, 27(2): 80-81. DOI:10.1093/neuonc/nos295. [3] 况艺,孙艳玲,荆凤, 等. 癌症相关经济毒性概念分析[J]. 护理研究, 2021, 35(20): 3695-3700. DOI:10.12102/j.issn.1009-6493.2021.20.025. [4] Nogueira LA, Machado CaM, Marques A, et al. Implications of financial toxicity in the lives of cancer patients: a reflection[J]. Rev Gaucha Enferm, 2021, 42: e20200095. DOI:10.1590/1983-1447.2021.20200095. [5] De Souza JA, Yap BJ, Hlubocky FJ, et al.The development of a financial toxicity patient-reported outcome in cancer: The COST measure[J]. Cancer, 2014, 120(20):3245-3253. DOI:10.1002/cncr.28814. [6] 于慧会,毕雪,刘运泳. 中文版癌症患者报告结局的经济毒性量表信度和效度研究[J].中华流行病学杂志, 2017, 38(8):1118-1120. DOI:10.3760/cma.j.issn.0254-6450.2017.08.024. [7] Khera R, Valero-Elizondo J, Nasir K.Financial toxicity in atherosclerotic cardiovascular disease in the United States: current state and future directions[J]. J Am Heart Assoc, 2020, 9(19): e017793. DOI: 10.1161/JAHA.120.017793. [8] Valero-Elizondo J, Chouairi F, Khera R, et al.Atherosclerotic cardiovascular disease, cancer, and financial toxicity among adults in the United States[J]. JACC Cardio Oncol, 2021, 3(2): 236-246. DOI: 10.1016/j.jaccao.2021.02.006. [9] Bloomfeld RS, Bickston SJ.Financial toxicity in people with inflammatory bowel disease[J]. Inflammatory Bowel Diseases, 2020, 27(7): 1170-1171. DOI: 10.1093/ibd/izaa267. [10] Bergeron M, Ishman SL.Persistent obstructive sleep apnea burden on family finances and quality of life[J]. Otolaryngol Head Neck Surg, 2021, 165(3):483-489. DOI:10.1177/0194599820986566. [11] Carrera PM, Kantarjian HM, Blinder VS.The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment[J]. CA Cancer J Clin, 2018, 68(2):153-165. DOI:10.3322/caac.21443. [12] 戴国琳,巴桑吉巴,马爽. 我国抗癌药价格高昂的原因及相关措施研究[J].中国药事, 2020, 34(8): 956-961. DOI:10.16153/j.1002-7777.2020.08.015. [13] Anon.Monthly and median costs of cancer drugs at the time of FDA approval 1965-2016[J]. J Natl Cancer Inst, 2017, 109(8). DOI: 10.1093/jnci/djx173. [14] Zeng X, Peng L, Peng Y, et al.Economic evaluation of adding daratumumab to a regimen of bortezomib + dexamethasone in relapsed or refractory multiple myeloma: based on the latest updated analysis of CASTOR[J]. Clin Ther, 2020, 42(2):251-262. DOI:10.1016/j.clinthera.2019.12.007. [15] 何玉梅,李薇,朱贺, 等. 百令胶囊联合西医常规治疗方案治疗慢性肾衰竭的药物经济学研究[J].中国药事, 2022, 36(8): 862-871. DOI:10.16153/j.1002-7777.2022.08.003. [16] Jain T, Litzow MR.No free rides: management of toxicities of novel immunotherapies in ALL,including financial[J].Hematology Am Soc Hematol Educ Program, 2018,2018(1): 25-34. DOI:10.1182/asheducation-2018.1.25. [17] Abrams HR, Durbin S, Huang CX, et al.Financial toxicity in cancer care: origins, impact, and solutions[J]. Transl Behav Med, 2021, 11(11): 2043-2054. DOI: 10.1093/tbm/ibab091. [18] Nipp RD, Lee H, Gorton E, et al.Addressing the financial burden of cancer clinical trial participation: longitudinal effects of an equity intervention[J]. Oncologist,2019,24(8):1048-1055. DOI: 10.1634/theoncologist.2019-0146. [19] Huey RW, George GC, Phillips P, et al.Patient-reported out-of-pocket costs and financial toxicity during early-phase oncology clinical trials[J]. Oncologist, 2021, 26(7): 588-596. DOI: 10.1002/onco.13767. [20] Yabroff KR, Guy GP Jr, Ekwueme DU, et al.Annual patient time costs associated with medical care among cancer survivors in the United States[J]. Med Care, 2014, 52(7): 594-601. DOI: 10.1097/MLR.0000000000000151. [21] Tien T, Gkougkousis E, Allchorne P, et al.The use of healthcare services by prostate cancer patients in the last 12 months of life: how do we improve the quality of care during this period?[J]. J Palliat Care, 2021, 36(2): 93-97. DOI: 10.1177/0825859720975944. [22] Lee A, Shah K, Chino F.Assessment of parking fees at National Cancer Institute-designated cancer treatment centers[J]. JAMA Oncol, 2020, 6(8):1295-1297. DOI:10.1001/jamaoncol.2020.1475. [23] Sweet E.Debt-related financial hardship and health[J]. Health Educ Behav, 2021, 48(6): 885-891. DOI: 10.1177/1090198120976352. [24] Van Beek FE, Wijnhoven LMA, Holtmaat K, et al.Psychological problems among cancer patients in relation to healthcare and societal costs: a systematic review[J]. Psychooncology, 2021, 30(11):1801-1835. DOI:10.1002/pon.5753. [25] Casilla-Lennon MM, Choi SK, Deal AM, et al.Financial toxicity among patients with bladder cancer: reasons for delay in care and effect on quality of life[J]. J Urol, 2018, 199(5): 1166-1173. DOI: 10.1016/j.juro.2017.10.049. [26] Luyckx VA, Miljeteig I, Ejigu AM, et al.Ethical challenges in the provision of dialysis in resource-constrained environments[J]. Semin Nephrol, 2017, 37(3): 273-286. DOI: 10.1016/j.semnephrol.2017.02.007. [27] Nguyen NH, Khera R, Dulai PS, et al.ational estimates of financial hardship from medical bills and cost-related medication nonadherence in patients with inflammatory bowel diseases in the United States[J]. Inflamm Bowel Dis, 2021, 27(7): 1068-1078. DOI: 10.1093/ibd/izaa266. [28] Osborn CY, Kripalani S, Goggins KM, et al.Financial strain is associated with medication nonadherence and worse self-rated health among cardiovascular patients[J]. J Health Care Poor Underserved, 2017, 28(1): 499-513. DOI: 10.1353/hpu.2017.0036. [29] Inguva S, Priyadarshini M, Shah R, et al.Financial toxicity and its impact on health outcomes and caregiver burden among adult cancer survivors in the USA[J]. Future Oncol, 2022, 18(13): 1569-1581. DOI: 10.2217/fon-2021-1282. [30] Alshammari B, Noble H, Mcaneney H, et al.An exploration of symptom burden and its management, in Saudi Arabian patients receiving haemodialysis, and their caregivers: a mixed methods study protocol[J]. BMC Nephrol, 2019, 20(1): 250. DOI: 10.1186/s12882-019-1424-9. [31] Koskinen JP, Färkkilä N, Sintonen H, et al.The association of financial difficulties and out-of-pocket payments with health-related quality of life among breast, prostate and colorectal cancer patients[J]. Acta Oncol, 2019, 58(7): 1062-1068. DOI: 10.1080/0284186X.2019.1592218. [32] 袁静,林梦月,杨斌,等.前列腺癌患者经济毒性在自我效能与生活质量间的中介效应研究[J].解放军护理杂志, 2022,39(1):4-8.DOI:10.3969/j.issn.1008-9993.2022.01.002. [33] Parker C, Berkovic D, Ayton D, et al.Patient perceived financial burden in hematological malignancies: a systematic review[J]. Curr Oncol, 2022, 29(6): 3807-3824. DOI: 10.3390/curroncol29060305. [34] Ikonomou M, Skapinakis P, Balafa O, et al.The impact of socioeconomic factors on quality of life of patients with chronic kidney disease in Greece[J]. J Ren Care, 2015, 41(4): 239-246. DOI: 10.1111/jorc.12132. [35] Ng MSN, Chan DNS, Cheng Q, et al.Association between financial hardship and symptom burden in patients receiving maintenance dialysis: a systematic review[J].Int J Environ Res Public Health, 2021, 18(18). DOI:10.3390/ijerph18189541. [36] Hart NH, Smith AB, Hobbs K, et al.Juggling cancer and life in survivorship: the role of general practitioners[J]. Aust J Gen Pract, 2021, 50(8): 520-525. DOI: 10.31128/AJGP-04-21-5938. [37] Regueiro M, Click B, Anderson A, et al.Reduced unplanned care and disease activity and increased quality of life after patient enrollment in an inflammatory bowel disease medical home[J]. Clin Gastroenterol Hepatol, 2018, 16(11): 1777-1785. DOI: 10.1016/j.cgh.2018.04.007. |
| [1] | . [J]. Journal of Nursing, 2024, 31(15): 62-67. |
| [2] | ZHOU Yue, ZHANG Jie, PAN Yu-fan, DAI Yu, SUN Yu-jian, XIAO Yi, YU Yu-feng. Prediction models for risk of acquired weakness in mechanically ventilated patients: a systematic review [J]. Journal of Nursing, 2024, 31(6): 56-61. |
| [3] | HUANG Xin, YU Li-jun, ZHANG Er-ming, HA Li-na. Current status of energy intake in patients with stable COPD and its influencing factors [J]. Journal of Nursing, 2024, 31(5): 12-16. |
| [4] | WU Lin-mei, LIANG Zhi-jin, LIU Rui-jie, ZHONG Jing-jing, QIU Yu-hua. Barriers to and facilitators of exercise rehabilitation in patients with COPD: a CFIR-based systematic review [J]. Journal of Nursing, 2024, 31(5): 44-49. |
| [5] | HOU Ya-tian, CHEN Si-nuo, LIU Meng-hui, ZHANG Bo-wen, AN Xiang, LIU Yun, XU Wen-qi, ZHANG Ming-yang. Best evidence summary for identification and prevention of silent aspiration in mechanically ventilated patients [J]. Journal of Nursing, 2023, 30(18): 36-41. |
| [6] | . [J]. Journal of Nursing, 2023, 30(17): 29-33. |
| [7] | . [J]. Journal of Nursing, 2023, 30(13): 59-64. |
| [8] | . [J]. Journal of Nursing, 2023, 30(10): 46-51. |
| [9] | . [J]. Journal of Nursing, 2023, 30(6): 72-78. |
| [10] | HOU xiang-chuan, WU yan-ting, ZHOU kai-qi, MO yi-jian, HUANG li-xiang, LIU yi-sha. Best Evidence-based Practice for Improving Qualified Rate of Sputum Collection in Patients with with Respiratory Diseases [J]. Journal of Nursing, 2022, 29(24): 43-48. |
| [11] | HONG Li-wei, HOU Chun-yi, SHEN Xiang-xiang, ZHANG Hui-jin, ZHANG Qing, JU Chun-rong, HUANG Dan-xia. Best Evidence Summary for Prevention and Management of Complication in Discharged Patients after Lung Transplantation [J]. Journal of Nursing, 2022, 29(18): 47-52. |
| [12] | . [J]. Journal of Nursing, 2022, 29(16): 55-60. |
| [13] | . [J]. Journal of Nursing, 2022, 29(13): 46-51. |
| [14] | YANG Yang, LIU Ning. Best Evidence Summary for Nursing Assessment and Management of Acupoint Application for “Treatment of Winter Diseases in Summer” for Treating Bronchial Asthma [J]. Journal of Nursing, 2022, 29(5): 15-21. |
| [15] | . [J]. Journal of Nursing, 2021, 28(15): 30-34. |
|
||